S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
The "King Of Quants" sees 10X potential... (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The "King Of Quants" sees 10X potential... (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
The "King Of Quants" sees 10X potential... (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The "King Of Quants" sees 10X potential... (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
The "King Of Quants" sees 10X potential... (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The "King Of Quants" sees 10X potential... (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
The "King Of Quants" sees 10X potential... (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
The "King Of Quants" sees 10X potential... (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The "King Of Quants" sees 10X potential... (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
NASDAQ:CTIC

CTI BioPharma - CTIC Stock Forecast, Price & News

$4.44
+0.10 (+2.30%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.30
$4.50
50-Day Range
$4.34
$6.01
52-Week Range
$3.32
$7.80
Volume
1.77 million shs
Average Volume
3.12 million shs
Market Capitalization
$585.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
140.2% Upside
$10.67 Price Target
Short Interest
Bearish
10.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.53mentions of CTI BioPharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.78 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.18) to $0.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

692nd out of 988 stocks

Pharmaceutical Preparations Industry

330th out of 482 stocks


CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

CTI BioPharma (NASDAQ:CTIC) Upgraded at StockNews.com
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
CTIC CTI BioPharma Corp.
CTIC.OQ - | Stock Price & Latest News | Reuters
CTI BioPharma to Present at Upcoming November Conferences
CTI BioPharma: Q3 Earnings Snapshot
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Company Calendar

Last Earnings
3/06/2023
Today
3/20/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
22
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+140.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-92,990,000.00
Net Margins
-172.37%
Pretax Margin
-172.37%

Debt

Sales & Book Value

Annual Sales
$53 million
Book Value
($0.14) per share

Miscellaneous

Free Float
118,389,000
Market Cap
$585.37 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Adam R. CraigAdam R. Craig
    President, CEO, Director & Chief Medical Officer
  • David H. Kirske
    Chief Financial Officer & Executive Vice President
  • Jim Fong
    Chief Commercial Officer & Executive VP
  • John Volpone
    Senior Vice President-Strategic Operations













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2023?

6 equities research analysts have issued 12-month price targets for CTI BioPharma's stock. Their CTIC share price forecasts range from $9.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next year. This suggests a possible upside of 140.2% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How have CTIC shares performed in 2023?

CTI BioPharma's stock was trading at $6.01 at the start of the year. Since then, CTIC stock has decreased by 26.1% and is now trading at $4.44.
View the best growth stocks for 2023 here
.

Are investors shorting CTI BioPharma?

CTI BioPharma saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 13,500,000 shares, an increase of 6.6% from the February 13th total of 12,660,000 shares. Based on an average daily volume of 2,810,000 shares, the short-interest ratio is currently 4.8 days.
View CTI BioPharma's Short Interest
.

When is CTI BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CTIC earnings forecast
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) posted its quarterly earnings data on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analysts' expectations of $24.88 million. CTI BioPharma had a negative trailing twelve-month return on equity of 5,105.50% and a negative net margin of 172.37%. During the same quarter in the prior year, the company posted ($0.38) EPS.

What ETFs hold CTI BioPharma's stock?
When did CTI BioPharma's stock split?

Shares of CTI BioPharma reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.89%), Lion Point Capital LP (2.92%), Geode Capital Management LLC (1.51%), Point72 Asset Management L.P. (1.39%), Schonfeld Strategic Advisors LLC (1.38%) and Verition Fund Management LLC (1.15%). Insiders that own company stock include Adam R Craig, Bvf Partners L P/Il, David Kirske, James K Fong, Michael A Metzger and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of CTI BioPharma?

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $4.44.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $585.37 million and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 3/21/2023 by MarketBeat.com Staff